Multi-cancer early detection using cell-free DNA methylome analysis

使用游离 DNA 甲基化分析进行多癌症早期检测

基本信息

项目摘要

PROJECT SUMMARY Detecting cancer early is the best way to fight against cancer. The development of the Multi-Cancer Early Detection (MCED) liquid biopsy tests holds great promise for integrating early cancer detection into routine clinical care. However, the current MCED tests have unsatisfactory performance for early-stage cancers. Recently, we have developed a sensitive and cost-effective technology, named cell-free DNA Methylome Sequencing (cfMethyl-Seq), which uses the cell-free DNA methylome for early cancer detection. cfMethyl-Seq provides >12-fold enrichment over whole genome bisulfite sequencing in CpG islands. We performed the proof- of-principle study by applying cfMethyl-seq to a cohort of colon, liver, lung, and stomach cancer patients and controls, and obtained promising results in detecting and locating these cancer types. Here, we will further improve the cfMethyl-seq technology and apply it to detect and locate colon, gastric, liver, and lung cancer. We will validate this MCED test in multiple clinical cohorts. Our multidisciplinary team proposes the following aims: (1) Continued improvement of the cfMethyl-seq assay for early cancer detection. (2) Continued improvement of our computational method to analyze the cfDNA methylome assay data. (3) Clinically validate the cfDNA Methylome assay as an MCED assay with colon/gastric/liver/lung cancers as the first indications. (4) Contribute to Collaborative Trans-consortium Activities. We have a long-standing collaboration with the industry partner, EarlyDiagnostics, which will optimize the cfMethyl-seq assay to facilitate its clinical adoption and implement the computational algorithm in a secure cloud computing platform to facilitate data sharing and decentralized testing.
项目摘要 早期发现癌症是对抗癌症的最佳方法。早期多癌的研究进展 液体活检检测(MCED)为将早期癌症检测纳入常规检查提供了很大的希望 临床护理然而,目前的MCED测试对早期癌症的表现并不令人满意。 近年来,我们发展了一种高灵敏度和低成本的技术,命名为无细胞DNA甲基化组 测序(cfMethyl-Seq),使用游离DNA甲基化组进行早期癌症检测。cfMethyl-Seq 在CpG岛中提供超过全基因组亚硫酸氢盐测序的>12倍富集。我们做了证明- 通过将cfMethyl-seq应用于结肠癌、肝癌、肺癌和胃癌患者队列的原理研究, 对照,并在检测和定位这些癌症类型方面取得了可喜的成果。在这里,我们将进一步 改进cfMethyl-seq技术,并将其应用于结肠癌、胃癌、肝癌和肺癌的检测和定位。我们 将在多个临床队列中验证此MCED测试。我们的多学科团队提出了以下目标: (1)持续改进cfMethyl-seq检测方法用于早期癌症检测。(2)继续改善 我们的计算方法来分析cfDNA甲基化组测定数据。(3)临床验证cfDNA 甲基化组测定作为MCED测定,结肠癌/胃癌/肝癌/肺癌作为第一适应症。(4)贡献 跨财团合作活动。我们与行业合作伙伴有着长期的合作关系, EarlyDiagnostics将优化cfMethyl-seq检测试剂盒,以促进其临床应用,并实施 在安全的云计算平台中使用一种计算算法,以促进数据共享和分散测试。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT S BRESALIER其他文献

ROBERT S BRESALIER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT S BRESALIER', 18)}}的其他基金

Colorectal cancer risk factors, risk prediction and blood-based biomarker by tumor consensus molecular subtype
按肿瘤共有分子亚型分类的结直肠癌危险因素、风险预测和血液生物标志物
  • 批准号:
    10591999
  • 财政年份:
    2019
  • 资助金额:
    $ 95.26万
  • 项目类别:
Colorectal cancer risk factors, risk prediction and blood-based biomarker by tumor consensus molecular subtype
按肿瘤共有分子亚型分类的结直肠癌危险因素、风险预测和血液生物标志物
  • 批准号:
    10021547
  • 财政年份:
    2019
  • 资助金额:
    $ 95.26万
  • 项目类别:
Integrated Signaling in Pancreatic Cancer Progression
胰腺癌进展中的整合信号转导
  • 批准号:
    9493432
  • 财政年份:
    2016
  • 资助金额:
    $ 95.26万
  • 项目类别:
Integrated Signaling in Pancreatic Cancer Progression
胰腺癌进展中的整合信号转导
  • 批准号:
    10018467
  • 财政年份:
    2016
  • 资助金额:
    $ 95.26万
  • 项目类别:
Integrated Signaling in Pancreatic Cancer Progression
胰腺癌进展中的整合信号转导
  • 批准号:
    10247023
  • 财政年份:
    2016
  • 资助金额:
    $ 95.26万
  • 项目类别:
Integrated Signaling in Pancreatic Cancer Progression
胰腺癌进展中的整合信号传导
  • 批准号:
    9266771
  • 财政年份:
    2016
  • 资助金额:
    $ 95.26万
  • 项目类别:
Molecular Mediators of Pancreatic Cancer Invasion and Progression
胰腺癌侵袭和进展的分子介质
  • 批准号:
    9250086
  • 财政年份:
    2013
  • 资助金额:
    $ 95.26万
  • 项目类别:
MUCIN GLYCOPROTEINS IN COLON CANCER METASTASIS
结肠癌转移中的粘蛋白糖蛋白
  • 批准号:
    6686311
  • 财政年份:
    2002
  • 资助金额:
    $ 95.26万
  • 项目类别:
Great Lakes New England Clinical Validation Center
新英格兰五大湖临床验证中心
  • 批准号:
    10484455
  • 财政年份:
    2000
  • 资助金额:
    $ 95.26万
  • 项目类别:
Great Lakes New England Clinical Validation Center
新英格兰五大湖临床验证中心
  • 批准号:
    10698103
  • 财政年份:
    2000
  • 资助金额:
    $ 95.26万
  • 项目类别:

相似海外基金

Genome analysis-based prediction model development for response to stereotactic radiosurgery in benign brain tumors
基于基因组分析的预测模型开发,用于良性脑肿瘤立体定向放射外科治疗的反应
  • 批准号:
    23K08495
  • 财政年份:
    2023
  • 资助金额:
    $ 95.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
高风险良性乳腺诊断女性的临床乳腺癌风险预测模型
  • 批准号:
    10719777
  • 财政年份:
    2023
  • 资助金额:
    $ 95.26万
  • 项目类别:
Environmentally Benign Precise Transformations of Alkenes by Chiral Chalcogenide Catalysts
手性硫属化物催化剂对环境无害的烯烃精确转化
  • 批准号:
    22KJ2498
  • 财政年份:
    2023
  • 资助金额:
    $ 95.26万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Learners to LeAders in benign Urology, benign Nephrology, and non-Cancer Hematology
良性泌尿外科、良性肾脏病学和非癌症血液学领域的学习者和领导者
  • 批准号:
    10726042
  • 财政年份:
    2023
  • 资助金额:
    $ 95.26万
  • 项目类别:
The role of estrogen receptor alpha in prostatic fibrosis contributing to benign prostatic hyperplasia
雌激素受体α在导致良性前列腺增生的前列腺纤维化中的作用
  • 批准号:
    10607151
  • 财政年份:
    2023
  • 资助金额:
    $ 95.26万
  • 项目类别:
Development of a medical device to resolve benign esophageal stricture by heating and traction
开发通过加热和牵引解决良性食管狭窄的医疗设备
  • 批准号:
    23H03765
  • 财政年份:
    2023
  • 资助金额:
    $ 95.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of benign/malignant differentiation method for thyroid follicular tumor using organoids
利用类器官开发甲状腺滤泡性肿瘤良恶性鉴别方法
  • 批准号:
    23K08075
  • 财政年份:
    2023
  • 资助金额:
    $ 95.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic Tumorigenesis
p53在散发性肿瘤发生良性向恶性转变中的参与和作用机制
  • 批准号:
    10720034
  • 财政年份:
    2023
  • 资助金额:
    $ 95.26万
  • 项目类别:
I-Corps: Mitigating Multidrug Resistant Bacterial Infections with Biocompatible and Environmentally Benign Nanoantibiotics
I-Corps:利用生物相容性且对环境无害的纳米抗生素减轻多重耐药细菌感染
  • 批准号:
    2306943
  • 财政年份:
    2023
  • 资助金额:
    $ 95.26万
  • 项目类别:
    Standard Grant
Identifying the role of the gut microbiome in the etiology of benign breast disease
确定肠道微生物组在良性乳腺疾病病因学中的作用
  • 批准号:
    10359959
  • 财政年份:
    2022
  • 资助金额:
    $ 95.26万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了